Amy Meng

480 total citations · 1 hit paper
11 papers, 247 citations indexed

About

Amy Meng is a scholar working on Genetics, Oncology and Rheumatology. According to data from OpenAlex, Amy Meng has authored 11 papers receiving a total of 247 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 5 papers in Oncology and 4 papers in Rheumatology. Recurrent topics in Amy Meng's work include Chronic Lymphocytic Leukemia Research (7 papers), Cytokine Signaling Pathways and Interactions (5 papers) and Rheumatoid Arthritis Research and Therapies (4 papers). Amy Meng is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Cytokine Signaling Pathways and Interactions (5 papers) and Rheumatoid Arthritis Research and Therapies (4 papers). Amy Meng collaborates with scholars based in United States. Amy Meng's co-authors include Julie A. Di Paolo, Bernard P. Murray, Federico Campigotto, Paqui G. Través, René Galien, Anita Mathias, Sandra A. Lewis, Richard L. Mackman, John Ling and Brian P. Kearney and has published in prestigious journals such as Annals of the Rheumatic Diseases, Clinical Pharmacology & Therapeutics and British Journal of Clinical Pharmacology.

In The Last Decade

Amy Meng

9 papers receiving 245 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib

2021 218 citations Paqui G. Través, Bernard P. Murray et al. Annals of the Rheumatic Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amy Meng United States	4	122	91	61	49	47	11	247
TRDJ Radstake Netherlands	10	118 1.0×	52 0.6×	97 1.6×	35 0.7×	47 1.0×	20	268
Julie Ducreux Belgium	9	144 1.2×	46 0.5×	121 2.0×	21 0.4×	26 0.6×	14	267
Nathalie Gunera-Saad France	6	83 0.7×	88 1.0×	114 1.9×	32 0.7×	18 0.4×	7	304
Michelle Ki United States	5	44 0.4×	65 0.7×	46 0.8×	34 0.7×	24 0.5×	8	347
Cornelis E. Hack Netherlands	7	51 0.4×	20 0.2×	148 2.4×	96 2.0×	61 1.3×	8	295
Lubing Zhu China	4	268 2.2×	55 0.6×	401 6.6×	21 0.4×	34 0.7×	5	504
Karen Hambardzumyan Sweden	9	225 1.8×	22 0.2×	63 1.0×	43 0.9×	58 1.2×	15	282
Kseniya Petrova‐Drus United States	7	24 0.2×	54 0.6×	31 0.5×	43 0.9×	53 1.1×	20	183
Georgios L. Moschovakis Germany	6	49 0.4×	91 1.0×	206 3.4×	21 0.4×	32 0.7×	6	322
Nobuya Hiraoka Japan	9	24 0.2×	74 0.8×	76 1.2×	44 0.9×	43 0.9×	22	254

Countries citing papers authored by Amy Meng

Since Specialization

Citations

This map shows the geographic impact of Amy Meng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Meng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Meng more than expected).

Fields of papers citing papers by Amy Meng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Meng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Meng. The network helps show where Amy Meng may publish in the future.

Co-authorship network of co-authors of Amy Meng

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Meng. A scholar is included among the top collaborators of Amy Meng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Meng. Amy Meng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

1.

Meng, Amy, Cara Nelson, Liyun Ni, et al.. (2022). Exposure‐response relationships for the efficacy and safety of filgotinib and its metabolite GS‐829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies. British Journal of Clinical Pharmacology. 88(7). 3211–3221. 7 indexed citations

2.

Través, Paqui G., Bernard P. Murray, Federico Campigotto, et al.. (2021). JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Annals of the Rheumatic Diseases. 80(7). 865–875. 218 indexed citations breakdown →

3.

Simpson, L., Bernard P. Murray, Amy Meng, et al.. (2021). POS0224 SELECTIVITY OF CLINICAL JAK INHIBITORS AND THE IMPACT ON NATURAL KILLER (NK) CELL FUNCTIONAL RESPONSES. Annals of the Rheumatic Diseases. 80. 331–331. 3 indexed citations

4.

Meng, Amy, Rita Humeniuk, Juliane M. Jürgensmeier, et al.. (2021). Semi‐Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA. Clinical Pharmacology & Therapeutics. 111(2). 416–424. 3 indexed citations

5.

Murray, Bernard P., et al.. (2020). THU0067 JAK SELECTIVITY AND THE IMPACT ON CYTOKINE SIGNALING INHIBITION AT CLINICAL RHEUMATOID ARTHRITIS DOSES. Annals of the Rheumatic Diseases. 79. 246–246. 2 indexed citations

6.

Clarke, Astrid, et al.. (2020). P460 Evaluation of potential mechanisms underlying the safety observations of filgotinib in clinical studies in rheumatoid arthritis. Journal of Crohn s and Colitis. 14(Supplement_1). S409–S409.

7.

Meng, Amy, Cara Nelson, Brian J. Kirby, et al.. (2020). SAT0149 EXPOSURE-RESPONSE RELATIONSHIPS FOR EFFICACY AND SAFETY OF FILGOTINIB AND ITS METABOLITE GS-829845 IN SUBJECTS WITH RHEUMATOID ARTHRITIS BASED ON PHASE 2 AND PHASE 3 STUDIES. Annals of the Rheumatic Diseases. 79. 1013–1014. 1 indexed citations

8.

Meng, Amy, et al.. (2019). THU0017 IN VITRO MECHANISTIC STUDIES DEMONSTRATE FILGOTINIB ACTIVITY THAT HAS POTENTIAL IMPLICATIONS FOR DIFFERENTIATION AMONG JAK INHIBITORS. Annals of the Rheumatic Diseases. 78. 276–276. 2 indexed citations

9.

Begley, Rebecca, Amy Meng, Benedetta Massetto, et al.. (2019). IDDF2019-ABS-0135 Pharmacokinetics of once-daily sofosbuvir or ledipasvir/sofosbuvir in HCV-infected pediatrics aged 3 to. A137.2–A138. 2 indexed citations

10.

German, Polina, Jason W. Chien, Richard L. Mackman, et al.. (2018). Phase 1 First‐in‐Human, Single‐ and Multiple‐Ascending Dose, and Food Effect Studies to Assess the Safety, Tolerability, and Pharmacokinetics of Presatovir for the Treatment of Respiratory Syncytial Virus Infection. The Journal of Clinical Pharmacology. 58(8). 1025–1034. 9 indexed citations

11.

Meng, Amy. (2016). For the Dead. 36(1). 1–1.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact